On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading
Executive Orders 1944. President Roosevelt. Executive Order No. 9424, Establishment of a Register of Government Interests in Patents. Source: The provisions of Executive Order 9424. February 18, 1944, at 9 FR 1959, 3 CFR, 1943-1948 Comp., p. 303, unless otherwise… Continue Reading
Re: Clinical trial cost request, June 2019 In June 2019, KEI reached out to Dr. Jerry Mendell in an effort to obtain information on clinical trial costs. June 19, 2019 Email from Laurel Boman at KEI to Dr. Jerry Mendell… Continue Reading
On Monday July 29, 2019, Knowledge Ecology International (KEI) submitted joint comments to the NIH on behalf of KEI, Social Security Watch (SSW), Universities Allied for Essential Medicines (UAEM), Union for Affordable Cancer Treatment (UACT), and Clare Love, a cancer… Continue Reading
This is a copy of the “We PAID Act” by Senators Chris van Hollen (D-MD) and Rick Scott (R-FL). The We PAID Act The 31 page bill creates a new non-profit organization to determine reasonable prices for drugs that use… Continue Reading
On July 22, 2019, Knowledge Ecology International submitted a letter to the US House of Representative’s Committee on Oversight and Reform regarding the National Institutes of Health’s (NIH) lack of transparency in its exclusive licensing processes. Prior to executing an… Continue Reading
On July 2, 2019, KEI and UACT submitted comments to the Federal Register notice 84 FR 28063 on the “Prospective Grant of Exclusive Patent License: Lutetium-177 Radiotherapeutics Against Somatostatin-Receptor Expressing Neuroendocrine Tumors” from the National Institutes of Health (NIH). The proposed… Continue Reading
UPDATE: On July 11, 2019, KEI received the following letter in response to the comments below: Response to KEI_7-11-19 On July 2, 2019, KEI and UACT submitted comments to the Federal Register notice 84 FR 28063, on the “Prospective Grant… Continue Reading
UPDATE: On 4 July 2019, the Core Group will submit a “TABLING REV 1” version of their resolution on “Access to medicines and vaccines in the context of the right of everyone to the enjoyment of the highest attainable standard… Continue Reading
On June 7, 2019, KEI and UACT submitted comments to the Federal Register notice 84 FR 23798, on the “Prospective Grant of an Exclusive Patent License: The Development and Use of a Therapeutic STAT3 Inhibitor, GLG-302, in All Proliferative Diseases,… Continue Reading
Zolgensma, Novartis’s new $2.1 million gene therapy for children with spinal muscular atrophy (SMA), is a remarkable breakthrough with a steep price tag: the cost per child is $2.125 million. The treatment was developed using research funded by the National… Continue Reading